Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...

Recombinant human leukocyte antigen class II histocompatibility antigen (HLA-DRA) has been implicated in the development of various cancers, but its specific role in ...

Square-planar, four-coordinate metal complexes strip peptides from the binding site of MHC class II molecules. Removal of peptides derived from self-antigens could prevent class II–dependent ...

While previous research has proven the role of MHC-I molecules, a new study in Cell suggests that MHC-II may also serve as a target in immunotherapy. Patient-specific variations in MHC-II molecules ...

Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

Researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, have developed a new approach ...

The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

A new perspective argues that antigen-presenting fibroblasts in gastrointestinal tumors are reversible states whose immune ...

MHC-I presents peptides derived from endogenous antigens. Antigen is proteolyzed by the immune proteasome and specific peptides loaded to MHC-I. The resulting MHC-I–peptide complex is transported to ...

Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...

Newswise — Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse ...